Response Assessment Scan Timing After RAI Therapy for Well-Differentiated Thyroid Cancer

A post-therapy whole-body scan (WBS) should be performed immediately after RAI administration (within 3-7 days), followed by the first formal response assessment at 6-12 months using neck ultrasound and stimulated thyroglobulin levels. 1, 2

Immediate Post-Therapy Assessment

Post-therapy WBS is mandatory immediately after RAI administration because it upstages disease in 6-13% of cases by detecting previously unidentified metastatic foci 1. This scan should be performed:

3-5 days after therapeutic RAI dose 2
Using the radioactivity from the therapeutic dose itself (not requiring additional tracer)
With slow-speed imaging (6-8 cm/min, at least 30 minutes) 2

This immediate post-therapy scan is critical because it provides information that cannot be obtained from pre-therapy diagnostic scans and directly influences subsequent management decisions.

First Formal Response Assessment (6-12 Months)

The initial response assessment occurs at 6-12 months after RAI therapy and includes 1, 2:

Core Components:

Neck ultrasound (first-line imaging modality)
Stimulated thyroglobulin (Tg) measurement after rhTSH stimulation
Anti-thyroglobulin antibodies
Clinical examination

Risk-Stratified Approach to Additional Imaging:

Low-Risk Patients:

If excellent response (undetectable Tg <0.2 ng/mL on suppression or <1 ng/mL after stimulation + negative ultrasound), no further WBS needed 1
Recurrence risk <5% in this group 1
Periodic WBS not necessary with normal ultrasound and low Tg 1

Intermediate/High-Risk Patients:

WBS has a role in evaluating initial response to RAI ablation 1
Consider diagnostic WBS at 6-12 months if:
- Post-ablation WBS showed insufficient information due to high thyroid bed uptake 2
- Suspicious uptake foci on post-therapy scan 2
- Persistent anti-Tg antibodies 2
- Extra-thyroid RAI uptake on post-therapy WBS 3

Subsequent Surveillance Schedule

After excellent response to therapy:

Annual follow-up with TSH, Tg, and anti-Tg antibodies 2
Periodic neck ultrasound based on risk stratification 1
No routine surveillance WBS if excellent response achieved 1

For detectable but low Tg (below institutional threshold, typically 5-7 ng/mL):

Repeat rhTSH-stimulated Tg at 12 months 2
Additional ultrasound surveillance 2

For elevated Tg or rising antibodies:

Immediate additional imaging (see recurrence evaluation) 1

Critical Pitfalls to Avoid

Do not skip the immediate post-therapy WBS - it provides unique diagnostic information unavailable from other modalities and changes management in a significant minority of patients 1
Do not perform routine diagnostic WBS in low-risk patients with excellent response - this represents unnecessary radiation exposure without clinical benefit 1, 3
Do not rely solely on Tg in patients with anti-Tg antibodies - these patients require imaging-based surveillance including periodic diagnostic WBS 2
Do not use CT or MRI as initial imaging - neck ultrasound is the first-line modality for post-treatment surveillance 1
Do not perform FDG-PET/CT for routine surveillance - reserve this for patients with elevated Tg (>10 ng/mL) and negative RAI imaging 3, 4

Special Considerations

Timing of stimulated Tg measurement:

Performed 3 days after second rhTSH injection 2
Can be done on levothyroxine therapy (no withdrawal needed with rhTSH) 2

Diagnostic WBS technique when indicated:

Use 150-185 MBq (4-5 mCi) I-131 or I-123 2
I-123 preferred for better image quality if available 1
Perform 2 days after administration 2

The evidence strongly supports this tiered, risk-stratified approach that balances thorough disease assessment against unnecessary radiation exposure and healthcare costs. The 2019 ACR Appropriateness Criteria 1 provide the most comprehensive and recent guideline framework for this surveillance strategy.

When should a response assessment scan be performed after radioactive iodine (RAI) therapy for well‑differentiated thyroid cancer?

Have a follow-up question?